Today, the three major stock indices opened on a positive note. The market witnessed a flurry of activities across various sectors. Stocks related to solid – state batteries shot up rapidly in the early trading, driving the sector to the forefront of gainers. This upward momentum in solid – state battery stocks comes as the industry continues to show promise in terms of technological advancements and potential market expansion. With their advantages of high safety and high energy density, solid – state batteries are tipped to trigger a new round of innovation in the electrification space, as noted in relevant research reports.
In the financial sector, there were fluctuations followed by strengthening. However, gold, banks, non – ferrous metals, and fertilizers emerged as the leading losers. The decline in gold prices might be influenced by various factors such as changes in the US dollar’s strength and market sentiment towards safe – haven assets.
Yue Hong Yuan A experienced a sudden straight – line plunge, leading to a trading halt today. Its latest stock price stands at 4.08 yuan per share, with a total market value of 2.6 billion yuan. On the evening of June 6th, the company made an announcement that it intends to call off the acquisition of approximately 60% of the shares of Bochu Intelligent Equipment Co., Ltd. through cash payment. Currently, Yue Hong Yuan A is mainly engaged in real estate development and sales, along with the operation of lead recycling. Bochu Intelligent, on the other hand, focuses on the production of intelligent injection molding equipment, which falls under the high – end equipment manufacturing industry within the strategic emerging industries category.
CRO stocks stole the show by leading the gains in both markets. In the morning trading, the CRO index soared by 5.41%, outperforming all other sectors. Rui Zhi Medicine achieved a “20cm” daily limit, while Meinova and Lianhua Technology also hit their respective daily highs. Jin Kai Shengke, Shenguo Biology, Wanbang Medicine, and Hao Yuan Medicine, among others, closely trailed the upward trend. The positive performance of CRO stocks is likely attributed to recent developments in the pharmaceutical industry. At the 2025 American Clinical Oncology Society (ASCO) conference, there was a record – high number of 73 oral presentations from China. Additionally, after San Sheng Pharmaceutical completed a transaction worth over 6 billion US dollars, Shigong Group announced that it is advancing a total of 5 billion US dollars in BD cooperation with an independent third party, involving the licensing of multiple drug projects, including EGFR – ADC, which is expected to be finalized in June.
According to Huafu Securities, from 2020 to 2024, the total transaction amount of innovative drug licensing agreements witnessed a substantial increase, rising from 9.2 billion US dollars to 52.3 billion US dollars. The upfront payment amount also climbed from 600 million US dollars to 4.1 billion US dollars. Since 2025, the total transaction amount of innovative drugs going global has reached 45.5 billion US dollars, with the upfront payment hitting 2.2 billion US dollars, and it is anticipated to reach a new annual high.
A research report by China Galaxy Securities pointed out that the pharmaceutical sector has endured a long – term adjustment. Currently, overall valuations are at a relatively low level, and public funds’ holdings in this sector are under – allocated. In 2025, with policy support and guidance for the development of commercial insurance, the payment side is expected to show marginal improvement. As a result, innovative drugs and medical devices are likely to benefit. The pharmaceutical market is projected to experience a sustained recovery, and structural opportunities remain. Based on the certainty of growth in the short – term and medium – to – long – term, by choosing targets with clear growth prospects, the industry is optimistic about the continued strong performance of the innovative drug industry this year.
The performance of multiple stocks is forecasted to show significant growth in the next two years. According to statistics by Data Treasure of Securities Times, innovative drug stocks have demonstrated robust performance in terms of stock prices this year, with an average increase of 27.34%, far outpacing the overall market. Six stocks have seen their stock prices double within the year. Among them, Shutai Shen led the pack with a cumulative rise of 292.98% this year. Stocks such as Sansheng Guojian, Kexing Pharmaceutical, and Lianhua Technology all recorded price increases of more than 100% this year.
Related Topic:
